NASDAQ:ESPR Esperion Therapeutics (ESPR) Stock Price, News & Analysis $1.87 +0.06 (+3.31%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.86 -0.02 (-0.80%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Esperion Therapeutics Stock (NASDAQ:ESPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Esperion Therapeutics alerts:Sign Up Key Stats Today's Range$1.70▼$1.8850-Day Range$0.92▼$1.9252-Week Range$0.69▼$3.94Volume5.15 million shsAverage Volume5.63 million shsMarket Capitalization$370.63 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingModerate Buy Company Overview Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Read More Esperion Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreESPR MarketRank™: Esperion Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 178th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingEsperion Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Esperion Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.29) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.35% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Esperion Therapeutics has recently decreased by 8.03%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-2.76 Percentage of Shares Shorted11.35% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Esperion Therapeutics has recently decreased by 8.03%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.63 News SentimentEsperion Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Esperion Therapeutics this week, compared to 4 articles on an average week.Search Interest11 people have searched for ESPR on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,184.00 in company stock.Percentage Held by InsidersOnly 1.70% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Esperion Therapeutics' insider trading history. Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Stock News HeadlinesCantor Fitzgerald Has Positive View of ESPR FY2025 Earnings5 hours ago | americanbankingnews.comHC Wainwright Issues Positive Outlook for ESPR Earnings5 hours ago | americanbankingnews.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 9 at 2:00 AM | The Oxford Club (Ad)Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)August 7 at 5:30 PM | globenewswire.comEsperion (ESPR) Q2 Revenue Jumps 12%August 5, 2025 | fool.comEsperion rises after revenue beat, Q1 profitability expectationAugust 5, 2025 | seekingalpha.comEsperion Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 5, 2025 | globenewswire.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $7.00 Average PT from AnalystsAugust 3, 2025 | americanbankingnews.comSee More Headlines ESPR Stock Analysis - Frequently Asked Questions How have ESPR shares performed this year? Esperion Therapeutics' stock was trading at $2.20 at the beginning of 2025. Since then, ESPR shares have decreased by 15.0% and is now trading at $1.87. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) posted its quarterly earnings results on Tuesday, August, 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.15. The biopharmaceutical company earned $82.39 million during the quarter, compared to analyst estimates of $62.55 million. Esperion Therapeutics had a negative net margin of 35.84% and a negative trailing twelve-month return on equity of 0.91%. Read the conference call transcript. Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' top institutional shareholders include Geode Capital Management LLC (2.31%), Summit Wealth Group LLC (0.16%), UMB Bank n.a. (0.09%) and Parallel Advisors LLC (0.06%). Insiders that own company stock include Benjamin Halladay, Benjamin Looker, Sheldon L Koenig, Eric Warren, Joanne M Foody and J Martin Carroll. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Esperion Therapeutics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and AU Optronics (AUOTY). Company Calendar Last Earnings8/05/2025Today8/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ESPR CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Price Target for Esperion Therapeutics$7.00 High Price Target$16.00 Low Price Target$3.00 Potential Upside/Downside+274.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.74 million Net Margins-35.84% Pretax Margin-59.03% Return on Equity-0.91% Return on Assets-28.84% Debt Debt-to-Equity RatioN/A Current Ratio1.18 Quick Ratio0.81 Sales & Book Value Annual Sales$332.31 million Price / Sales1.12 Cash Flow$0.02 per share Price / Cash Flow75.33 Book Value($1.97) per share Price / Book-0.95Miscellaneous Outstanding Shares198,200,000Free Float194,830,000Market Cap$370.63 million OptionableOptionable Beta0.82 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ESPR) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.